A significant international study involving 23,000 participants has uncovered troubling links between widely used medications and adverse outcomes for patients undergoing treatment for breast cancer. Researchers from the University of South Australia (UniSA) and Flinders University conducted the analysis, which focused on how common drugs, including those for blood pressure, cholesterol, and heartburn, may influence cancer therapy effectiveness.
The study, published in Cancer Medicine, highlights that proton pump inhibitors (PPIs), often prescribed for heartburn and indigestion, are associated with a 36% higher risk of severe side effects and poorer overall survival rates in breast cancer patients. Researchers speculate that these medications could disrupt the body’s immune response or affect the absorption and metabolism of cancer treatments, though additional research is necessary to confirm these findings.
Medications Impacting Treatment Outcomes
In addition to PPIs, the study identified other medications linked to increased rates of severe side effects for breast cancer patients. These include beta-blockers, ACE inhibitors, angiotensin receptor blockers, and calcium-channel blockers—commonly used for managing heart disease and hypertension. Despite these associations, these medications did not appear to impact overall survival rates.
Conversely, drugs like statins and metformin, frequently used for cholesterol and diabetes management, showed no significant effects on survival or adverse events, suggesting they remain safe options for patients.
The comprehensive analysis drew data from 19 major clinical trials sponsored by pharmaceutical companies such as Lilly, Pfizer, and Roche. This research is considered one of the largest and most thorough studies of its kind globally.
Expert Insights and Recommendations
Lead author Dr. Natansh Modi emphasized the complexity of medication interactions in breast cancer treatment. “Many women with breast cancer are also managing other chronic conditions such as high blood pressure, diabetes, or acid reflux,” he stated. “This means they are often taking multiple drugs at once. Our results do not suggest that patients should stop taking their non-cancer medications, but they highlight the importance of regular medication reviews by healthcare providers.”
Senior author Associate Professor Ashley Hopkins noted that patients using PPIs in oncology settings should be monitored more closely. “It is essential that patients do not discontinue their reflux medications without consulting their healthcare provider,” he said. “Clinicians should remain vigilant regarding potential risks and assess the necessity of PPIs.”
The findings underscore the need for a more comprehensive approach to breast cancer management that takes into account all medications a patient may be using. The researchers advocate for follow-up studies to explore the biological mechanisms behind the observed drug interactions and to develop clinical guidelines for safely prescribing these medications alongside cancer therapies.
For further details, refer to the study: Natansh D. Modi et al, “Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer,” published in Cancer Medicine (2025). DOI: 10.1002/cam4.71320.
